文献速递临床试验与 GCP流行病学与生物统计

冷却时长对心脏骤停患者疗效的影响(ICECAP):一项多中心、随机、适应性分配临床试验的研究方案,旨在确定诱导性低温神经保护的最佳时长,用于院外心脏骤停后昏迷的成年幸存者

Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrest.
PubMed 文献 · Trials · 2024-07-23

ICECAP是一项多中心、随机、反应适应性、时长(剂量)探索的比较效果临床试验,采用盲法结局评估,计划最大样本量1800例,比较院外心脏骤停后昏迷成年幸存者12、24、48小时诱导性低温时长,主要终点为加权90天改良Rankin量表(mRS)评分,旨在确定提供最大治疗效应的最短冷却时长。

要点

  • 研究比较12、24、48小时诱导性低温时长,采用反应适应性随机分配。
  • 主要终点为加权90天mRS评分,评估神经功能残疾。
  • 计划最大样本量1800例,按初始心律类型(可除颤或不可除颤)分层分配。

核心结论

  • 假设更长的冷却时长可能改善获得良好神经功能恢复的患者比例,或改善已被归类为良好结局患者的恢复程度。
  • 若冷却的治疗效应随时长增加而增加,则即使无常温对照臂,也提供冷却本身有效的证据,证实既往针对可除颤心律院外心脏骤停幸存者的随机对照试验,并首次为初始不可除颤心律者提供前瞻性对照疗效证据。

研究设计与样本

  • 多中心、随机、反应适应性、时长(剂量)探索、比较效果临床试验,采用盲法结局评估。
  • 研究两种成年心脏骤停后昏迷幸存者人群,以确定提供最大治疗效应的最短冷却时长。
  • 设计基于以主要终点(加权90天mRS)定义的统计反应模型。
  • 受试者初始按12、24、48小时治疗性冷却等比例随机分配。
  • 首200例受试者随机分配后,开放12至48小时之间的额外治疗臂,并在每种初始心律类型(可除颤或不可除颤)内通过反应适应性随机分配患者。

主要发现

  • 美国每年超过380000例患者发生院外心脏骤停。
  • 关键随机临床试验中,对昏迷患者进行诱导性冷却显著改善了神经功能和功能结局,但治疗性低温的最佳时长尚未确立。
  • 次要目标为描述与冷却时长相关的总体安全性和不良事件、对神经心理学结局的影响以及对患者报告的生活质量指标的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac arrest is a common and devastating emergency of both the heart and brain. More than 380,000 patients suffer out-of-hospital cardiac arrest annually in the USA. Induced cooling of comatose patients markedly improved neurological and functional outcomes in pivotal randomized clinical trials, but the optimal duration of therapeutic hypothermia has not yet been established. METHODS: This study is a multi-center randomized, response-adaptive, duration (dose) finding, comparative effectiveness clinical trial with blinded outcome assessment. We investigate two populations of adult comatose survivors of cardiac arrest to ascertain the shortest duration of cooling that provides the maximum treatment effect. The design is based on a statistical model of response as defined by the primary endpoint, a weighted 90-day mRS (modified Rankin Scale, a measure of neurologic disability), across the treatment arms. Subjects will initially be equally randomized between 12, 24, and 48 h of therapeutic cooling. After the first 200 subjects have been randomized, additional treatment arms between 12 and 48 h will be opened and patients will be allocated, within each initial cardiac rhythm type (shockable or non-shockable), by response adaptive randomization. As the trial continues, shorter and longer duration arms may be opened. A maximum sample size of 1800 subjects is proposed. Secondary objectives are to characterize: the overall safety and adverse events associated with duration of cooling, the effect on neuropsychological outcomes, and the effect on patient-reported quality of life measures. DISCUSSION: In vitro and in vivo studies have shown the neuroprotective effects of therapeutic hypothermia for cardiac arrest. We hypothesize that longer durations of cooling may improve either the proportion of patients that attain a good neurological recovery or may result in better recovery among the proportion already categorized as having a good outcome. If the treatment effect of cooling is increasing across duration, for at least some set of durations, then this provides evidence of the efficacy of cooling itself versus normothermia, even in the absence of a normothermia control arm, confirming previous RCTs for OHCA survivors of shockable rhythms and provides the first prospective controlled evidence of efficacy in those without initial shockable rhythms. TRIAL REGISTRATION: ClinicalTrials.gov NCT04217551. Registered on 30 December 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Meurer WJ, Schmitzberger FF, Yeatts S, et al. Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP): study protocol for a multicenter, randomized, adaptive allocation clinical trial to identify the optimal duration of induced hypothermia for neuroprotection in comatose, adult survivors of after out-of-hospital cardiac arrest. Trials. 2024. PMID: 39044295. doi:10.1186/s13063-024-08280-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。